MA31198B1 - Nouvelle forme dosifiee - Google Patents

Nouvelle forme dosifiee

Info

Publication number
MA31198B1
MA31198B1 MA32184A MA32184A MA31198B1 MA 31198 B1 MA31198 B1 MA 31198B1 MA 32184 A MA32184 A MA 32184A MA 32184 A MA32184 A MA 32184A MA 31198 B1 MA31198 B1 MA 31198B1
Authority
MA
Morocco
Prior art keywords
new
dosified
dosage form
neurological
preparation
Prior art date
Application number
MA32184A
Other languages
Arabic (ar)
English (en)
Inventor
Allan James Clarke
David Geoffrey Cullingford
Yu Li
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA31198B1 publication Critical patent/MA31198B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une nouvelle forme dosifiée, un procédé destiné à la préparation de cette forme dosifiée et l'utilisation de cette forme dosifiée dans le traitement de troubles neurologiques et psychiatriques.
MA32184A 2007-03-01 2009-08-31 Nouvelle forme dosifiee MA31198B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89226707P 2007-03-01 2007-03-01
PCT/EP2008/052430 WO2008104590A2 (fr) 2007-03-01 2008-02-28 Nouvelle forme dosifiée

Publications (1)

Publication Number Publication Date
MA31198B1 true MA31198B1 (fr) 2010-02-01

Family

ID=39248198

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32184A MA31198B1 (fr) 2007-03-01 2009-08-31 Nouvelle forme dosifiee

Country Status (30)

Country Link
US (1) US20110014283A1 (fr)
EP (1) EP2131818B1 (fr)
JP (2) JP5743177B2 (fr)
KR (1) KR101504371B1 (fr)
CN (1) CN101674806B (fr)
AR (1) AR065529A1 (fr)
AU (1) AU2008220795B2 (fr)
BR (1) BRPI0807882A2 (fr)
CA (1) CA2679529A1 (fr)
CL (1) CL2008000596A1 (fr)
CO (1) CO6220900A2 (fr)
CR (1) CR11013A (fr)
DK (1) DK2131818T3 (fr)
DO (1) DOP2009000207A (fr)
EA (1) EA019865B1 (fr)
ES (1) ES2463468T3 (fr)
HK (1) HK1137363A1 (fr)
HR (1) HRP20140390T1 (fr)
IL (1) IL200619A (fr)
MA (1) MA31198B1 (fr)
MX (1) MX2009009362A (fr)
NZ (1) NZ579374A (fr)
PE (1) PE20090114A1 (fr)
PL (1) PL2131818T3 (fr)
PT (1) PT2131818E (fr)
SI (1) SI2131818T1 (fr)
TW (1) TWI424856B (fr)
UA (1) UA102515C2 (fr)
WO (1) WO2008104590A2 (fr)
ZA (1) ZA200905866B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
BRPI0712823A2 (pt) 2006-06-23 2012-07-24 Abbott Lab derivados de ciclopropil amina como moduladores de receptor de histamina h3
WO2010023170A1 (fr) * 2008-08-29 2010-03-04 Glaxo Group Limited Forme posologique comprenant de la 1-isopropyl-4-{[4-(tétrahydro-2h-pyran-4-yloxy)phényl]carbonyl}hexahydro-1h-1,4-diazépine ou un sel de celle-ci
US9186353B2 (en) * 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
WO2011051423A1 (fr) 2009-11-02 2011-05-05 Glaxo Group Limited Traitement ou prophylaxie de la démence, des troubles neurodégénératifs, de la schizophrénie, de l'adhd de la somnolence ou de l'épilepsie
WO2012037258A1 (fr) 2010-09-16 2012-03-22 Abbott Laboratories Procédés de préparation de dérivés cyclopropyliques substitués en 1,2
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
AU2015362790A1 (en) 2014-12-16 2017-07-20 Axovant Sciences Gmbh Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
RU2017145964A (ru) 2015-06-10 2019-07-10 Аксовант Сайенсиз Гмбх Аминобензизоксазольные соединения в качестве агонистов α7-никотиновых ацетилхолиновых рецепторов
WO2017027600A1 (fr) 2015-08-12 2017-02-16 Forum Pharmaceuticals, Inc. Composés d'aminobenzisoxazole à substitution géminale utilisés en tant qu'agonistes de récepteurs de l'acétylcholine α7-nicotinique

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE227122T1 (de) * 1993-09-03 2002-11-15 Smithkline Beecham Corp Stabilisierte tablettenformulierung
AU776299B2 (en) * 1998-12-01 2004-09-02 Dr Reddy's Laboratories, Inc. New pharmaceutical composition and the process for its preparation
US20040037869A1 (en) * 2002-08-16 2004-02-26 Douglas Cleverly Non-animal product containing veterinary formulations
RU2423353C1 (ru) * 2002-12-20 2011-07-10 Глэксо Груп Лимитед Новые производные бензазепина
EP2332920A3 (fr) * 2003-06-17 2011-12-21 Arena Pharmaceuticals, Inc. Procédés de préparation de 3-benzazepines
US20070021391A1 (en) * 2003-06-30 2007-01-25 Takayuki Doi Preventive/remedy for urinary disturbance
WO2005042491A1 (fr) * 2003-10-22 2005-05-12 Arena Pharmaceuticals, Inc. Derives de benzazepine et methodes de prophylaxie ou traitement de maladies associees au recepteur 5ht2c
US20060002986A1 (en) * 2004-06-09 2006-01-05 Smithkline Beecham Corporation Pharmaceutical product
PE20060302A1 (es) * 2004-06-18 2006-04-08 Glaxo Group Ltd Derivados de benzazepina como antagonistas del receptor h3
JP2006022039A (ja) * 2004-07-08 2006-01-26 Towa Yakuhin Kk 高い安定性を有するシンバスタチン固形製剤
GB0418267D0 (en) * 2004-08-16 2004-09-15 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
CN101674806A (zh) 2010-03-17
EP2131818B1 (fr) 2014-04-09
AU2008220795B2 (en) 2013-06-06
BRPI0807882A2 (pt) 2014-06-17
IL200619A0 (en) 2010-05-17
DOP2009000207A (es) 2009-10-31
JP5743177B2 (ja) 2015-07-01
HRP20140390T1 (hr) 2014-06-06
TWI424856B (zh) 2014-02-01
TW200900093A (en) 2009-01-01
CL2008000596A1 (es) 2008-09-05
UA102515C2 (ru) 2013-07-25
EA200970817A1 (ru) 2010-06-30
JP2015038098A (ja) 2015-02-26
NZ579374A (en) 2012-01-12
MX2009009362A (es) 2009-09-14
EP2131818A2 (fr) 2009-12-16
IL200619A (en) 2014-09-30
WO2008104590A3 (fr) 2009-07-02
WO2008104590A2 (fr) 2008-09-04
DK2131818T3 (da) 2014-05-26
ES2463468T3 (es) 2014-05-28
CR11013A (es) 2009-12-15
AR065529A1 (es) 2009-06-10
PE20090114A1 (es) 2009-04-13
US20110014283A1 (en) 2011-01-20
CN101674806B (zh) 2013-03-13
CO6220900A2 (es) 2010-11-19
KR101504371B1 (ko) 2015-03-19
JP2010520174A (ja) 2010-06-10
HK1137363A1 (en) 2010-07-30
ZA200905866B (en) 2010-05-26
PL2131818T3 (pl) 2014-08-29
PT2131818E (pt) 2014-06-05
EA019865B1 (ru) 2014-06-30
CA2679529A1 (fr) 2008-09-04
KR20090127311A (ko) 2009-12-10
AU2008220795A1 (en) 2008-09-04
SI2131818T1 (sl) 2014-06-30

Similar Documents

Publication Publication Date Title
MA31198B1 (fr) Nouvelle forme dosifiee
TN2009000551A1 (fr) Nouveaux composes chimiques
TN2015000547A1 (fr) Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1
MA43756B1 (fr) Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine
MA30466B1 (fr) Nouvelle forme d'administration du racecadotril
MA30798B1 (fr) Thiazole pyrazolopyrimidines comme antigonistes du recepteur crf1
MA32655B1 (fr) Composés modulant sélectivement le récepteur cb2
FR13C0029I2 (fr) Compositions pour le traitement de troubles gastro-intestinaux
MA33450B1 (fr) Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques
MA28481B1 (fr) Dérivés d'imidazole pour le traitement de troubles neurodégénératifs
MA29772B1 (fr) Benzimidazoles substitues et procedes de preparation
TW200633708A (en) Thieno-pyridine derivatives as gaba-b allosteric enhancers
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA32506B1 (fr) Nouveaux composes
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
MA29169B1 (fr) Formulations intraveineuses d'inhibiteurs de la pde-5
TN2014000424A1 (fr) Agents pour le traitement de troubles impliquant la modulation des recepteurs de la ryanodine
MA29439B1 (fr) Derives d'uree d'heteroaryle utilises pour inhiber chk1
CL2007002899A1 (es) Compuestos derivados de azaciclilaminas n-sustituidas, inhibidores del receptor de histamina 3; proceso de preparacion; composicion farmaceutica que comprende los compuestos, y usopara el tratamiento de trastornos cognitivos, esquizofre nia y enfermedad de alzheimer entre otros.
MA38079A1 (fr) Composés de 2-phényl-5-hétérocyclyl-tétrahydro-2h-pyran-3-amine destinés à être utilisés dans le traitement du diabète et de ses troubles associés
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA28093A1 (fr) Forme polymorphe de 3-phenylsulfonyl-8-piperazine-1-yl-quinoleine
RS50578B (sr) Supstituisani 2-aminotetralini za preventivni tretman parkinsonove bolesti
MA30592B1 (fr) Nouvel extrait d'eucalyptus, son procede de preparation et ses utilisations therapeutiques
MA30037B1 (fr) Compositions et procedes destines au traitement des troubles du snc